Select Publications

Journal articles

Benza RL; Keogh AM; Ivy DD; Sandoval J; Barst RJ, 2006, '94', The Journal of Heart and Lung Transplantation, 25, pp. S76 - S76, http://dx.doi.org/10.1016/j.healun.2005.11.099

Zahir H; Keogh AM; Akhlaghi F, 2006, 'Apparent clearance of sirolimus in heart transplant recipients: Impact of primary diagnosis and serum lipids', Therapeutic Drug Monitoring, 28, pp. 614 - 622

Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil K; Celermajer DS, 2006, 'Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease', Cardiology in the Young, 16, pp. 268 - 274

Chua R; Keogh AM; Byth K; O Loughlin A, 2006, 'Comparsion and validation of three measures of quality of life in patients with pulmonary hypertension', Internal Medicine Journal, 36, pp. 705 - 710

Ray J; Keogh AM; McLachlan AJ, 2006, 'Decision support tool to individualise cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclospoine C2 monitoring', Journal of Heart and Lung Transplantation, 25, pp. 1223 - 1229

Wlodarczyk J; Cleland L; Keogh AM; McNeil K; Perl K; Weintraub R; Williams TJ, 2006, 'Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing', Pharmacoeconomics, 24, pp. 903 - 915

Kobashigawa J; Renlund D; Gerosa G; Almenar L; Eisen H; Keogh AM; Lehmkuhl H; Livi U; Ross H; Segovia J; Yonan N, 2006, 'Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: Results of a 12-month, single-blind, randomized, parallel-group, multicenter stud', Journal of Heart and Lung Transplantation, 25, pp. 935 - 941

Razonable RR; Brown RA; Humar A; Covington E; Alecock E; Paya CV; Eris J; Keogh A; Mathew T; McCaughan G; Nicholls K; Strasser S; Lalonde R; Marotta P; Preiksaitis J; Yoshida E; Gandjbakch I; Lebranchu Y; Legendre C; Saliba F; Traynor O; Angeli P; Menichetti F; Gane R; Bakran A; Forsythe J; Heaton N; Lodge P; Manas D; Morris P; Parameshwar J; Yonan N; Alexander B; Blumberg E; Brennan DC; Brown R; Busuttil RW; Chavin K; Conti D; DeMattos A; Dominguez E; Eisen HJ; Fishbein D; Fishbein T; Fisher R; Freeman R; Freise C; Hart M; Heffron T; Hershberger RE; Howard RJ; Kemmerly SA; Knight R; Kubak B; Kusne S; Mawhorter S; Mullen M; Pescovitz M; Pirsch J; Pruett TL; Punch J; Rabkin J; Rubin R; Scandling J; Shapiro M; Silibovsky R; Washburn K; Weinstein S, 2005, 'A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients', Journal of Infectious Diseases, 192, pp. 1349 - 1354, http://dx.doi.org/10.1086/466532

Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D, 2005, 'Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures - A randomised controlled trial', Heart Lung and Circulation, 14, pp. 245 - 251, http://dx.doi.org/10.1016/j.hlc.2005.06.007

Galie N; Badesch D; Oudiz R; Simonneau G; McGoon M; Keogh AM; Frost A; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin L, 2005, 'Ambrisentan therapy for pulmonary arterial hypertension', Journal of the American College of Cardiology, 46, pp. 529 - 535

Chua R; Keogh AM, 2005, 'Combining treprostinil and sildenafil in the treatment of pulmonary hypertension', Internal Medicine Journal, 35, pp. 684 - U3

Akhlaghi F; Zahir H; Keogh AM, 2005, 'Factors influencing dosing and concentrations of sirolimus in de novo heart transplant recipients', American Journal of Transplantation, 5, pp. 169 - 169

Keogh AM, 2005, 'Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors', Transplantation Proceedings, 37, pp. 1 - 3, http://www.sciencedirect.com/science/article/B6VJ0-4FVHVB1-1/2/55a5e31d9b1b3e2b6a712cc8143bf698

Badesch D; Zwicke D; Keogh AM; Galie N; Olschewski H; McGoon M; McLaughlin V; Oudiz R; Simonneau G; Rubin L; Frost A, 2005, 'Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases', Arthritis Care & Research, 52, pp. S166 - S166

Keogh AM, 2005, 'Long-term benefits of mycophenolate mofetil after heart transplantation', Transplantation, 79, pp. S45 - S46

Jabbour A; Schneider L; Mellemkjaer S; Hayward CS; Macdonald PS; Keogh AM, 2005, 'Long-term sildenafil use lowers elevated transpulmonary gradients in NYHA class IV heart failure patients allowing successful heart transplantation', Journal of Cardiac Failure, 11, pp. S134 - S134

Chua R; Keogh AM; Miyashita M, 2005, 'Novel use of sildenafil in the treatment of portopulmonary hypertension', Journal of Heart and Lung Transplantation, 24, pp. 498 - 500

Jiang L; Bardini M; Keogh AM; dos Remedios CG; Burnstock GS, 2005, 'P2X(1) receptors are closely associated with connexin 43 in human ventricular myocardium', International Journal of Cardiology, 98, pp. 291 - 297

Chua R; Keogh AM, 2005, 'Spinal Cord Stimulation Significantly Improves Refractory Angina Pectoris-A Local Experience: Spinal Cord Stimulation in Refractory Angina', Heart Lung and Circulation, 14, pp. 3 - 7, http://www.sciencedirect.com/science/article/B7CW2-4FJV22N-4/2/6b6b4c9181d27982bd0fab7cc4ec88f5

Eisen H; Kobashigawa J; Keogh AM; Bourge R; Renlund D; Mentzer R; Alderman E; Valantine H; Dureau G; Mancini D; Mamelok R; Gordon RB; Wang W; Mehra M; Constanzo M; Hummel M; Johnson JF, 2005, 'Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients', Journal of Heart and Lung Transplantation, 24, pp. 517 - 525

Keogh AM; Ruygrok PN, 2004, 'Importance of mammalian target of rapamycin inhibitors in the prevention of cardiac allograft vasculopathy', Current Opinion in Organ Transplantation, 9, pp. 389 - 393, http://dx.doi.org/10.1097/01.mot.0000145534.54912.6f

Keogh A; Wlodarczyk J, 2004, 'Idiopathic- and scleroderma-related pulmonary arterial hypertension: Outcomes and QOL on bosentan', Expert Review of Pharmacoeconomics and Outcomes Research, 4, pp. 505 - 513, http://dx.doi.org/10.1586/14737167.4.5.505

Browne N; Grocott P; Cowley S; Cameron J; Dealey C; Keogh A; Lovatt A; Vowden K; Vowden P, 2004, 'Woundcare Research for Appropriate Products (WRAP): Validation of the TELER method involving users', International Journal of Nursing Studies, 41, pp. 559 - 571, http://dx.doi.org/10.1016/j.ijnurstu.2003.12.009

Cox SA; Keogh AM, 2004, 'Patient and professional partnership in diabetic nephropathy', EDTNA-ERCA Journal, 30, pp. 166 - 168, http://dx.doi.org/10.1111/j.1755-6686.2004.tb00360.x

Keogh AM, 2004, 'Calcineurin inhibitors in heart transplantation', Journal of Heart and Lung Transplantation, 23, pp. S202 - S206, http://www.sciencedirect.com/science/article/B6VSG-4C5FTMN-4/2/de9e3eb6a345a357ce626720af954589

Chua R; O Loughlin AJ; Keogh AM; Brown KM; Corrigan C, 2004, 'Comparison and validation of three quality of life instruments for the functional assessment of pulmonary arterial hypertension', Journal of Heart and Lung Transplantation, 23, pp. S143 - S143, http://www.sciencedirect.com/science/article/B6VSG-4BJK13R-BM/2/f417d36bda8b4e9684645d30d56c574c

Tsubakihara M; Williams NK; Keogh AM; dos Remedios CG, 2004, 'Comparison of gene expression between left atria and left ventriclesfrom non-diseased humans', Proteomics, 4, pp. 261 - 270

Keogh A; Muller D; Faddy S; Ruygrok P; Richardson M; Galbraith A, 2004, 'HEART TRANSPLANT PATIENTS TREATED WITH SIROLIMUS IMMMUNOTHERAPY SHOW SIGNIFICANT REDUCTION IN THE PROGRESSION OF GRAFT VASCULOPATHY AT 2 YEARS', Transplantation, 78, pp. 160 - 160, http://dx.doi.org/10.1097/00007890-200407271-00421

Ghofrani H; Pepke-Zaba J; Barbera J; Channick R; Keogh AM; Gomez-Sanchez M; Kneussl M; Grimminger F, 2004, 'Nitric oxide pathway and phosphodiesterase inhibitors in pulmonaryarterial hypertension', Journal of the American College of Cardiology, 43, pp. 68S - 72S

Qasabian R; Meagher AP; Lee RW; Dore GJ; Keogh AM, 2004, 'Severe diverticulitis after heart, lung, and heart-lung transplantation', Journal of Heart and Lung Transplantation, 23, pp. 845 - 849

Keogh A; Muller D; Faddy S; Ruygrok P; Richardson M; Galbraith A, 2004, 'Sirolimus from the time of heart transplantation - persistent protection from graft vasculopathy at 2 years', The Journal of Heart and Lung Transplantation, 23, pp. S106 - S107, http://dx.doi.org/10.1016/j.healun.2003.11.194

Keogh AM; Richardson M; Ruygrok P; Spratt P; Galbraith A; O Driscoll G; Macdonald PS; Esmore D; Muller DW; Faddy S, 2004, 'Sirolimus in de novo heart transplant recipients reduces acuterejection and prevents coronary artery disease at 2 years - Arandomized clinical trial', Circulation, 110, pp. 2694 - 2700

Keogh AM; Muller DW; Faddy S; Ruygrok P; Richardson M; Galbraith A, 2004, 'Sirolimus provides protection from graft vasculopathy at 2 years afterheart transplantation', American Journal of Transplantation, 4, pp. 281 - 281

Kotlyar E; Hayward CS; Keogh AM; Feneley MP; Macdonald PS, 2004, 'The impact of baseline left ventricular size and mitral regurgitationon reverse left ventricular remodelling in response to carvedilol: sizedoesn`t matter', Heart, 90, pp. 800 - 801

Keogh AM; Macdonald PS; Williams T; McNeil K; Gabbay E; Proudman S; Steele PA; Wlodarczyk J; Trimble K, 2004, 'TRACLEER(R) (bosentan), for the treatment of pulmonary arterial hypertension (PAH) - 6 month quality of life data', Journal of Heart and Lung Transplantation, 23, pp. S54 - S54, http://www.sciencedirect.com/science/article/B6VSG-4BJK13R-18/2/c4e03edb8882660d8ad37686c58a3819

Ray JE; Keogh AM; McLachlan AJ; Akhlaghi F, 2003, 'Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors', Journal of Heart and Lung Transplantation, 22, pp. 715 - 722, http://dx.doi.org/10.1016/S1053-2498(02)00649-6

Kathryn Briffa N; Keogh AM; Sambrook PN; Eisman JA, 2003, 'Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol', Transplantation, 75, pp. 2133 - 2134, http://dx.doi.org/10.1097/01.TP.0000065179.06731.99

Keogh AM; McNeil KD; Williams T; Gabbay E; Cleland LG, 2003, 'Pulmonary arterial hypertension: A new era in management', Medical Journal of Australia, 178, pp. 564 - 567, http://dx.doi.org/10.5694/j.1326-5377.2003.tb05360.x

Arnold RH; Kotlyar E; Hayward C; Keogh AM; Macdonald PS, 2003, 'Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: A single centre, observational study', Heart, 89, pp. 293 - 298, http://dx.doi.org/10.1136/heart.89.3.293

Ruygrok PN; Webber B; Faddy S; Muller DW; Keogh A, 2003, 'Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression', Journal of Heart and Lung Transplantation, 22, pp. 1276 - 1279, http://dx.doi.org/10.1016/S1053-2498(02)01239-1

Wlodarczyk JH; Keogh A; Smith K; McCosker C, 2003, 'CHART: Congestive cardiac failure in hospitals an Australian review of treatment', Heart Lung and Circulation, 12, pp. 94 - 102, http://dx.doi.org/10.1046/j.1444-2892.2003.00197.x

Keogh A; Fenton S; Leslie C; Aboyoun C; Macdonald P; Zhao YC; Bailey M; Rosenfeldt F, 2003, 'Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure', Heart Lung and Circulation, 12, pp. 135 - 141, http://dx.doi.org/10.1046/j.1443-9506.2003.00189.x

Pincus M; Corrigan C; Macdonald PS; Hayward CS; Keogh AM, 2003, 'Bosentan increases warfarin dosing requirements in pulmonary hypertension', Journal of the American College of Cardiology, 41, pp. 225 - 225, http://dx.doi.org/10.1016/S0735-1097(03)81629-7

Allada C; Keogh AM; Kotlyar E; Hayward CS; Macdonald PS, 2003, 'Carvedilol in elderly heart failure patients', Heart, Lung and Circulation, 12, pp. 94 - 94

O Loughlin AJ; Pett SL; Anderson D; Yorke J; Chua R; Williams DB; Hayward CS; Keogh AM; Macdonald PS; Cunningham PH, 2003, 'Cytomegalovirus polymerase chain reaction tests can replace endoscopy and biopsy for the initial diagnosis of cytomegalovrius gastrointestinal disease in patients following heart transplantation', CSANZ

Pincus M; Nguyen TV; Keogh AM; Hayward CS; Feneley MP; Macdonald PS, 2003, 'Dobutamine stress echocardiography is predictive of events after heart transplantation', Journal of Heart and Lung Transplantation, 22, pp. 174 - 174

Allada C; Keogh AM; Kotlyar E; Macdonald PS, 2003, 'Efficacy, tolerability and long-term effects of carvedilol in women.', Heart, Lung and Circulation, 12, pp. 94 - 94, http://dx.doi.org/10.1046/j.1443-9506.2003.03544.x

Shafransky A; Keogh AM; Allada C; Hayward CS; Macdonald PS, 2003, 'Predictive factors of near normalisation of ejection fraction in patients with heart failure.', Heart, Lung and Circulation, 12, pp. 92 - 92

Wilson MK; Boyd DA; Macdonald PS; Keogh AM; Glanville AR, 2003, 'Pulmonary thromboendarterectomy in australia: Early results of the St Vincent`s programme', Thoracic Society

Briffa NK; Keogh AM; Sambrook PN; Eisman JA, 2003, 'Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol', Transplantation, 75, pp. 133 - 134


Back to profile page